

Hexavalent Chromium is Carcinogenic to F344/N Rats and B6C3F1 Mice Following Chronic Oral Exposure

Matthew D. Stout, Ronald A. Herbert, Grace E. Kissling, Bradley J. Collins, Gregory S. Travlos, Kristine L. Witt, Ronald L. Melnick, Kamal M. Abdo, David E. Malarkey and Michelle J. Hooth

**doi: 10.1289/ehp.0800208 (available at <http://dx.doi.org/>)
Online 31 December 2008**

**NIEHS**National Institute of
Environmental Health SciencesNational Institutes of Health
U.S. Department of Health and Human Services

**Hexavalent Chromium is Carcinogenic to F344/N Rats and B6C3F1 Mice Following
Chronic Oral Exposure**

Matthew D. Stout, Ronald A. Herbert, Grace E. Kissling, Bradley J. Collins, Gregory S. Travlos,
Kristine L. Witt, Ronald L. Melnick, Kamal M. Abdo, David E. Malarkey and Michelle J.

Hooth¹

National Toxicology Program, National Institute of Environmental Health Sciences, Research
Triangle Park, NC

¹Corresponding Author:

Dr. Michelle J. Hooth

NIEHS

PO Box 12233

MD EC-35

Research Triangle Park, NC 27709, USA

Phone: 919-316-4643

Fax: 919-541-4255

Email: hooth@niehs.nih.gov

Acknowledgements: This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences under Research Project Number 1 Z01 ES045004-11 BB. The authors wish to thank Drs. Paul Foster and Scott Masten for critical review of this manuscript. The authors do not have competing financial interests.

Running title: Oral Carcinogenicity of Hexavalent Chromium

Keywords: anemia, cancer, hexavalent chromium, histiocytic cellular infiltration, National Toxicology Program, oral cavity, small intestine

Abbreviations:

CPM	chromium picolinate monohydrate
Cr(III)	trivalent chromium
Cr(VI)	hexavalent chromium
H&E	hematoxylin and eosin
NTP	National Toxicology Program
SDD	sodium dichromate dihydrate
U. S. EPA	United States Environmental Protection Agency

Section Headings:

Abstract

Background

Objectives

Methods

Results

Conclusions

Introduction

Materials and Methods

Chemical and dose formulations

Animals and animal maintenance

Study design

Statistical methods

Results

Oral cavity neoplasms in rats

Small intestine neoplasms and hyperplasia in mice

Histiocytic infiltration in rats and mice

Hematology in rats and mice

In life effects in rats and mice

Discussion

References

Table 1

Table 2

Table 3

Table 4

Figure Legend

Figure 1

Abstract

Background: Hexavalent chromium (Cr(VI)) is a human carcinogen following inhalation exposure. Humans also ingest Cr(VI) from contaminated drinking water and soil; however, limited data exist on the oral toxicity and carcinogenicity of Cr(VI).

Objective: To characterize the chronic oral toxicity and carcinogenicity of Cr(VI) in rodents.

Methods: The National Toxicology Program (NTP) conducted 2-year drinking water studies of Cr(VI) (as sodium dichromate dihydrate) in male and female F344/N rats and B6C3F1 mice.

Results: Cr(VI) exposure resulted in increased incidences of rare neoplasms of the squamous epithelium that lines the oral cavity (oral mucosa and tongue) in male and female rats, and of the epithelium lining the small intestine in male and female mice. Cr(VI) exposure did not affect survival, but resulted in reduced mean body weights and water consumption, due at least in part to poor palatability of the dosed water. Cr(VI) exposure resulted in a transient microcytic hypochromic anemia in rats and a microcytosis in mice. Non-neoplastic lesions included diffuse epithelial hyperplasia in the duodenum and jejunum of mice and histiocytic cell infiltration in the duodenum, liver, and mesenteric and pancreatic lymph nodes of rats and mice.

Conclusions: Cr(VI) was carcinogenic following administration in drinking water to male and female rats and mice.

Introduction

Hexavalent chromium (Cr(VI)) compounds are classified as human carcinogens (Cohen et al. 1993; IARC 1990; NTP 1998), based on increased incidences of lung cancers in animals and humans following inhalation exposures. Inhalation exposures occur primarily in occupational settings. The highest exposure to Cr(VI) occurs occupationally to workers involved in chrome plating, chromate production, and stainless steel welding.

As a result of industrial contamination, concentrations of Cr(VI) in the drinking water and soil may be higher than concentrations resulting from natural sources alone, resulting in the ingestion of higher concentrations by populations residing near these locations than by the general population. A Cr(VI) concentration of 580 µg/L was found in a groundwater monitoring well in Hinkley, California (Pellerin and Booker 2000). Detectable levels of Cr(VI) have been reported in approximately 30% of the drinking water sources monitored in California, which has a 1 µg/L detection limit for purposes of reporting (CDPH 2007a); 86% of those sources had peak concentrations of 10 µg/L or less. The United States Environmental Protection Agency (U.S. EPA) has set a maximum contaminant level of 100 µg/L for total chromium in drinking water (ATSDR 2000). The limit in California and numerous other states is 50 µg/L of total chromium in drinking water (CDPH 2007b).

The toxicity of Cr(VI) in humans and animals has been reviewed extensively (ATSDR 2000; Costa 1997; Costa and Klein 2006; U.S. EPA, 1998). Only one lifetime animal carcinogenicity study was identified in the literature in which hexavalent chromium was administered in the drinking water (Borneff 1968). Further analysis of the data (Sedman et al. 2006) revealed that in three generations of female NMRI mice, the combined incidences of benign and malignant forestomach neoplasms were increased over controls; this study has

several limitations including high early mortality in the F0 generation as a result of ectromelia (mousepox) virus. A review of the few epidemiological studies that evaluated populations that were exposed to Cr(VI) in drinking water or in soil or slag fill concluded that these studies did not provide definitive evidence of an increase in cancer incidence or mortality rates (Proctor et al. 2002). However, a retrospective mortality study in China found higher incidences of lung and stomach neoplasms in populations people living near a chromium smelting plant compared to the general population (Zhang and Li 1987); statistical analysis of these data supported this conclusion (Beaumont et al. 2008; Sedman et al. 2006).

Because of concerns over its presence in drinking water source supplies, its potential health effects, including carcinogenicity, and the lack of adequate carcinogenicity studies by the oral route, the California Congressional Delegation, California Environmental Protection Agency, and the California Department of Health Services nominated Cr(VI) to the National Toxicology Program (NTP) for toxicity and carcinogenicity testing. Sodium dichromate dihydrate (SDD) was selected for testing because it is the primary base material for the production of chromium compounds, is widely used in industrial applications and is the most water soluble chromate.

The NTP previously conducted 3-month toxicity studies of SDD administered in drinking water (NTP 2007). F344/N rats and B6C3F1 mice were exposed to 0, 62.5, 125, 250, 500 or 1000 mg SDD/L. In these studies, there were reductions in body weight and water consumption and a microcytic hypochromic anemia in both rats and mice; the anemia was more severe in rats. Exposure-related histopathologic lesions included ulcers, epithelial hyperplasia and squamous metaplasia in the glandular stomach of rats, epithelial hyperplasia of the duodenum of mice and

histiocytic cellular infiltration in the liver, duodenum and pancreatic lymph node of rats and in the duodenum and mesenteric lymph node of mice.

Exposure concentrations for the 2-year studies of SDD were selected following review of the 3-month toxicity study data. The highest exposure concentration for the 2-year studies in rats and mice was limited by toxicity observed in the 3-month studies (NTP 2007) and a wider spacing of exposure concentrations was selected to extend the dose-response curve. An additional low exposure concentration group (5 mg Cr(VI)/L) was added to the 2-year studies to provide a concentration closer to human exposure through contaminated drinking water. This report presents the primary findings of the NTP chronic oral toxicity and carcinogenesis studies of Cr(VI) in male and female rats and mice; a more detailed report on these studies is available as an NTP technical report (NTP 2008a).

Materials and Methods

Chemical and dose formulations

SDD (CAS 7789-12-0) was obtained from Aldrich Chemical Company (Milwaukee, WI). The purity was determined using differential scanning calorimetry, titration of the dichromate ion with sodium thiosulfate and potassium ferrocyanide, speciation of the chromium ions using liquid chromatography-inductively coupled plasma-mass spectrometry and potentiometric titrimetric analysis with sodium thiosulfate. Based on these analyses, the overall purity was \geq 99.7%. The dose formulations were prepared approximately every 2 weeks by mixing SDD with tap water and stored at room temperature in sealed NALGENE® containers, protected from light. The dose formulations were stable for 42 days under these conditions. Periodic analysis by ultraviolet spectroscopy with detection at 350 to 390 nm confirmed that all dose formulations varied by less than 10% of the target concentrations.

Animals and animal maintenance

The studies were conducted at Southern Research Institute (Birmingham, AL). Male and female F344/N rats and B6C3F1 mice were obtained from Taconic Farms (Germantown, NY). Rats and mice were quarantined for 14 days and were 6-7 weeks old at the beginning of the studies. Animals were distributed randomly into groups of approximately equal initial mean body weights and identified by tail tattoo. Rats and mice were housed 1 (male mice), 3 (male rats) or 5 (female rats and mice) to a cage. Feed (irradiated NTP-2000 wafers; Zeigler Brothers, Inc., Gardners, PA) and tap water were available *ad libitum*. Animals were killed by carbon dioxide asphyxiation.

Animal use was in accordance with the United States Public Health Service policy on humane care and use of laboratory animals and the Guide for the Care and Use of Laboratory Animals. Animals were treated humanely and with regard for alleviation of suffering. These studies were conducted in compliance with the Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58).

Study design

Groups of 50 male and 50 female rats and mice were exposed to SDD in drinking water at concentrations of 0, 14.3, 57.3, 172, or 516 mg/L (male and female rats and female mice) or 0, 14.3, 28.6, 85.7, or 257.4 mg/L (male mice) for 105 to 106 weeks. Corresponding Cr(VI) concentrations are shown in Table 1. Water consumption was recorded weekly for the first 13 weeks and every 4 weeks thereafter with each water consumption measurement covering a 7-day period. Animals were weighed initially, weekly for the first 13 weeks, at 4-week intervals

thereafter, and at the end of the studies. Animals were observed twice daily and clinical findings were recorded at 4-week intervals beginning at week 5.

Complete necropsies and microscopic examinations were performed on all core study rats and mice. At necropsy, all organs and tissues were examined for grossly visible lesions, and all protocol-required tissues were fixed and preserved in 10% neutral buffered formalin (eyes were initially fixed in Davidson's solution), trimmed and processed, embedded in paraffin, sectioned to a thickness of 4 to 6 μm , and stained with hematoxylin and eosin (H&E) for microscopic examination. For all paired organs (e.g., adrenal gland, kidney, ovary), samples from each organ were examined. The entire gastrointestinal tract was opened and potential lesions were collected for microscopic evaluation. Oral mucosa and tongue are not protocol-required tissues; however, because gross lesions in these tissues were diagnosed as neoplasms, the oral mucosa and tongue of all animals were evaluated histologically. Additional details regarding the pathology data generation, quality assurance review, and NTP pathology working group are available elsewhere (NTP 2008a). Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). For subsequent analyses of the pathology data, the decision of whether to evaluate the diagnosed lesions for each tissue type separately or combined was generally based on the guidelines of McConnell et al. (1986).

Hematology and clinical chemistry were evaluated in additional groups of 10-16 male rats and female mice on days 4 (male rats only) and 22 and at 3, 6 and 12 months. At these time points, rats and mice were anesthetized with CO_2/O_2 , and blood was taken from the retroorbital sinus.

Statistical methods

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958). Animals found dead of other than natural causes or missing were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

The Poly-k test (Bailer and Portier 1988; Piegorsch and Bailer 1997; Portier and Bailer 1989) was used to assess neoplasm and nonneoplastic lesion incidence. This test is a survival-adjusted quantal-response procedure that modifies the Cochran-Armitage linear trend test to take survival differences into account; a value of $k=3$ was used in the analysis of site specific lesions. Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall exposure-related trend. Continuity-corrected Poly-3 tests were used in the analysis of lesion incidence, and reported P values are one sided. Sub- and supra-linear trends across doses for intestinal tumor rates were assessed with lack-of-fit tests for the linear regression of intestinal tumor rate on dose (Neter et al. 1996).

Hematology and clinical chemistry data, which have typically skewed distributions, were analyzed using the modified (Dunn 1964; Williams 1986) nonparametric multiple comparison methods of Shirley (1977). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Shirley 1977; Williams 1986) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunn 1964; Dunnett 1955). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey (1957) were examined by NTP personnel, and implausible values were eliminated from the analysis.

Results

Oral cavity neoplasms in rats

In male and female rats, there were significantly increased incidences of highly aggressive neoplasms of the squamous epithelium that lines the oral cavity (oral mucosa and tongue) at 516 mg/L (Table 2). Specifically, these increases were observed for squamous cell carcinoma in the oral mucosa, and for squamous cell papilloma or carcinoma (combined) of the oral mucosa or tongue of male and female rats at 516 mg/L. There were also squamous cell carcinomas in the oral mucosa of two 172 mg/L female rats; this incidence exceeded the historical control ranges for drinking water studies and for all routes of administration (Table 2). Nonneoplastic lesions were not observed in the oral mucosa.

Microscopically, the squamous cell carcinomas were highly invasive, irregular masses. Typically, they appeared to originate in the oral mucosa of the palate adjacent to the upper molar teeth and in some animals invaded the tongue, Harderian gland, and the soft tissues surrounding the nose, and in one case penetrated the maxilla and invaded the brain (Figure 1A and 1B). The squamous cell papillomas of the oral mucosa and tongue were exophytic masses that projected from the mucosa and consisted of irregular papillary proliferations of mature squamous epithelium supported by a core of fibrovascular stroma (Figure 1C).

Small intestine neoplasms and hyperplasia in mice

In both males and females, there was a clear exposure concentration-response for increased incidences of adenoma or carcinoma (combined) at all sites of the small intestine (duodenum, jejunum, or ileum) (Table 3). These increases were significant at 85.7 and 257.4 mg/L in males and at 172 and 516 mg/L females, the two highest exposure concentrations in

each sex. In addition, the incidence in 57.3 mg/L females exceeded the historical control ranges for drinking water studies and for all routes of administration (Table 3). These increases were driven primarily by significant increases in the incidences of adenoma of the duodenum in 257.4 mg/L males and 172 and 516 mg/L females; the number of mice with multiple adenomas was also significantly increased at the high dose in both sexes (data not shown). In females, the incidence of carcinoma in the duodenum was significantly increased at 516 mg/L. In the jejunum, the incidence of adenoma was increased in 516 mg/L females. For both males and females, the combined incidence of adenoma and carcinoma was tested for departures from a linear dose-response (data not shown). For males, the trend was linear and there was no significant departure from linearity. For females, there was a significant departure from linearity and the response was supra-linear.

Adenomas were discrete, broad based, focally extensive, plaque-like areas of proliferating glandular epithelium that thickened the mucosa and protruded into the lumen (Figure 1D). Carcinomas were sessile, plaque-like neoplasms distinguished from adenomas by extensive invasion and effacement of the mucous, underlying submucosa and muscle layers (Figure 1E).

Low incidences of focal epithelial hyperplasia occurred in the duodenum of exposed male and female mice (Table 4). Although the increased incidences were not exposure concentration-related or statistically significant, this lesion was considered a preneoplastic lesion related to exposure to SDD because of its morphologic similarities to adenoma. Focal epithelial hyperplasias were focal areas of proliferating glandular epithelium distinguished from adenomas because they were smaller, less discrete and confined to the superficial mucosal epithelium (Figure 1F).

The incidences of diffuse epithelial hyperplasia were significantly increased in the duodenum of all exposed groups of male and female mice (Table 4). In the jejunum, the incidence of diffuse epithelial hyperplasia was significantly increased in 516 mg/L females. In contrast to those of the controls (Figure 1G), the duodenums of exposed mice had short, broad, blunt villi, and generalized mucosal hypercellularity that was particularly prominent in the villi (Figure 1H).

Histiocytic infiltration in rats and mice

There were significant increases in histiocytic cell infiltration in the duodenum and mesenteric lymph node of rats and mice of both sexes, in the jejunum of female mice, in the liver of male and female rats and female mice, and in the pancreatic lymph node of female rats and male and female mice; this data is presented in detail in the [NTP technical report](#) (NTP 2008a).

The infiltrating histiocytes were morphologically similar in tissues of rats and mice. Histiocytic infiltrates were characterized by the presence of individual, small clusters and sometimes syncytia of large histiocytes (macrophages) within the sinusoids of the liver and lymph nodes and the lamina propria at the tips of the duodenal and jejunal villi. In the lymph nodes, the histiocytic infiltrates occurred as expansive sheets that in some cases replaced much of the lymph node parenchyma. The biological significance and cause of the histiocytic cellular infiltrates is unknown.

Hematology in rats and mice

In rats, an exposure-related decrease in mean cell volumes, mean cell hemoglobin concentrations, hematocrits, hemoglobin concentrations, and erythrocyte counts, and increase in

reticulocyte counts were indicative of an erythrocyte microcytic, hypochromic, responsive anemia; this data is presented in detail in the [NTP technical report](#) (NTP 2008a). The anemia was most prominent early in the study (22 days to 3 months). Microscopic evaluations of blood smears demonstrated increased poikilocytes, erythrocyte fragments/schizocytes, keratocytes, erythrocyte hypochromia, and microcytes that suggested increased erythrocyte injury or turnover. This effect was more prominent on day 22 and at 3 months than at 6 or 12 months, which may have either been a result of the animals adapting to exposure or a result of the decreased mg/kg doses with longer exposure durations. Mice demonstrated a similar, but less severe, effect on erythron.

In life effects in rats and mice

Survival, body weight and water consumption data are presented in detail in the [NTP technical report](#) (NTP 2008a). Survival of exposed groups of male and female rats and mice was similar to that of the respective control groups. Mean body weights compared to controls were decreased in male and female rats and mice. In rats, mean body weights of 516 mg/L males and females were less than those of controls throughout the study and by the end of the study were 12% (males) or 11% (females) less than the controls. Mean body weights of 257.4 mg/L male mice were less than controls for the first 4 months of the study, but were only slightly less (6%) by the end of the study. Mean body weights were less than the controls from months 3-12 in 172 mg/L female mice and from month 2 until the end of the study in 516 mg/L females. By the end of the study, mean body weights were 8% less than controls in 172 mg/L females and 15% less in 516 mg/L females.

The lower body weights were partly attributed to poor palatability of the dosed water and consequent reductions in water consumption rather than direct toxic effects of SDD exposure. Water consumption by male and female rats and mice exposed to the two highest concentrations was less than that by the controls throughout the study. No clinical findings were attributed to SDD exposure in rats or mice. When water consumption was adjusted for body weight (data not shown), dosed male and female rats and female mice drank approximately the same quantities of water/g body weight as the controls after the first 20 weeks on study. Male mice exposed to 257.4 mg/L drank less water/g body weight than the controls throughout the study.

Discussion

Humans are exposed to Cr(VI) through ingestion of contaminated water and soil; however, there is very little data on the oral toxicity and carcinogenicity of Cr(VI). The NTP conducted 3-month (NTP 2007) and 2-year (NTP 2008a) studies of SDD administered in the drinking water to F344/N rats and B6C3F1 mice, to provide data on the potential for toxic and carcinogenic effects following ingestion of Cr(VI).

Chronic administration of SDD in drinking water did not affect survival or produce clinical signs of toxicity in rats or mice. Exposure-related reductions in body weight gain and water consumption were observed for rats and mice in the highest exposure groups and were attributed partly to poor palatability of the dosed water. Several lines of evidence suggest that the animals were not dehydrated, including analysis of the water consumption data normalized to body weight, and the complete lack of clinical observations or hematologic or clinical chemistry effects (NTP 2008a) that typically indicate dehydration.

The NTP concluded that the exposure concentration-related significant increases in epithelial neoplasms of the upper alimentary tract (oral cavity) in male and female rats and of the

lower alimentary tract (small intestine) in male and female mice provided clear evidence of carcinogenic activity of SDD in male and female rats and mice. This conclusion was based on the increased neoplasm incidences relative to concurrent controls and the rarity of these neoplasms (see Tables 2 and 3) in historical controls. In both rats and mice, the conclusion was strengthened by similarities between the sexes. There were no increases in non-neoplastic histopathological lesions in either species suggestive of overt tissue damage due to the oxidant properties of Cr(VI).

There were obvious species differences in the target tissues for the development of neoplasms between rats and mice. Of the 21 chemicals that have caused neoplasms of the oral cavity in NTP studies, none produced these neoplasms in male mice and only one, 1,2,3-trichloropropane (NTP 1993), produced oral cavity neoplasms in female mice, demonstrating a greater sensitivity to the development of oral cavity neoplasms in rats relative to mice. Although slightly more common in rats, exposure-related increases of small intestine neoplasms in NTP studies are relatively rare in both species. The 2-year study of captan (NCI 1977) is the only other study performed by the NTP in B6C3F1 mice in which both benign and malignant intestinal neoplasms of epithelial origin have been definitely attributed to chemical exposure (Shackelford and Elwell 1999).

Although the induction of neoplasms following exposure to SDD was limited to the alimentary tract, other data, including the effects on the erythron and histiocytic cell infiltration in multiple tissues, provided evidence of systemic exposure and toxicity in male and female rats and mice exposed to Cr(VI) for 2 years. These lesions were also observed in the 3 month studies (NTP 2007).

As part of the NTP 2-year studies on SDD (NTP 2008a) and chromium picolinate monohydrate (CPM) (NTP 2008b), which contains trivalent Cr (Cr(III)), total chromium content was determined in selected tissues and excreta of additional groups of male rats and female mice; these data will be presented in detail in a companion manuscript. The goal of these studies was to examine the tissue uptake and distribution of Cr(VI) and Cr(III). Because Cr(VI) is reduced to Cr(III) both intracellularly and extracellularly and analytical methods for the separate analysis of Cr(VI) or Cr(III) in biological samples are not available, the speciation of the tissue chromium following exposure to Cr(VI) was inferred by comparing total chromium concentrations in tissues of rats and mice exposed to similar doses of Cr(VI) or Cr(III). Following oral exposure to Cr(VI), chromium accumulation was correlated with exposure concentration and duration in several tissues (NTP 2008a). Similar doses of Cr(VI) and Cr(III) resulted in significantly higher tissue chromium concentrations with Cr(VI), indicating that chromium was absorbed and distributed to tissues of rats and mice as Cr(VI); these data are consistent with previous studies (Costa 1997; Costa and Klein 2006). The tissue concentration data were consistent with linear or supra-linear (decreasing rate of response with increasing dose) dose responses. In the current studies, neither the oral cavity nor the small intestine was collected for total chromium analysis. However, other reports suggest that hexavalent chromium is also likely to be absorbed in the small intestine to a greater extent than trivalent chromium (Donaldson and Barreras 1966; Febel et al. 2001).

Reduction of Cr(VI) to the less permeable and bioavailable Cr(III) is thought to occur primarily in the stomach, as a mechanism of detoxification. Gastric reduction has been hypothesized to be efficient, such that oral exposure to Cr(VI) would not result in toxicity or carcinogenicity, except perhaps in the stomach (De Flora 2000; De Flora et al. 1997; Proctor et

al. 2002). Notably, in the 2-year study, no neoplasms or nonneoplastic lesions were observed in the forestomach or glandular stomach of rats or mice. However, the observed increases in neoplasms of the small intestine of mice and the systemic toxicity in the liver and blood suggest that under the conditions of this study, at least a portion of the administered Cr(VI) was not reduced in the stomach. The significant disparity in the oral toxicity and carcinogenicity of Cr(VI) and Cr(III) in rodents, including the absence of increases in neoplasms or non-neoplastic lesions of the small intestine in rats or mice exposed to CPM (NTP 2008b) provides additional evidence that Cr(VI) is not completely reduced in the stomach and is responsible for the observed effects.

Recently, De Flora and coworkers have suggested that increases in neoplasms of the small intestine observed in mice in the present study are the result of saturation of the gastric reduction capacity (De Flora et al. 2008). If such a threshold mechanism were to occur, the dose that saturated the reducing capacity would likely represent an inflection point on a sub-linear dose response curve, with doses above the inflection point demonstrating an increasing rate of response per unit dose, as unreduced chromium was transported into tissues. However, when tissue concentration and mouse small intestine neoplasm data were tested for linearity, data that were statistically non-linear were clearly supra-linear (decreasing rate of response per unit dose).

A reduction capacity of about 84-88 mg Cr(VI)/day has been estimated for human gastric juice (De Flora et al. 1997). This estimate was based on reported values of human secretion of gastric fluid per day during fasting and after consuming 3 meals/day in combination with experimental data on reduction of Cr(VI)/ml of gastric juice produced during these periods. Similar data are not available for Cr(VI) reduction by mouse gastric juice. However, assuming that Cr(VI) reduction is equally effective in mice and humans and that gastric secretion scales

across species by body weight^{3/4}, then the Cr(VI) reduction capacity of gastric juice from a 50 g mouse would be approximately 0.4 mg/day (~8 mg/kg/day). This value is above all of the male mouse doses and is nearly equivalent to the average daily dose of Cr(VI) in the high dose group of female mice in the 2-year drinking water study of SDD (see Table 1). Collectively, the dose response analysis and gastric reduction capacity calculations indicate that SDD induced neoplasms in the small intestine of mice at dose levels that did not exceed the estimated Cr(VI) reducing capacity for gastric juices in mice.

Cr(VI) is genotoxic in a number of in vitro and in vivo test systems (DeFlora et al. 1990; IARC 1990); however, the mechanisms of genotoxicity and carcinogenicity are not fully understood. Since Cr(VI) as chromate structurally resembles sulfate and phosphate, it can be taken up by all cells and organs throughout the body through nonspecific anion transporters (Costa 1997). Once inside the cell, indirect DNA damage may occur through the generation of oxygen radicals during intracellular reduction of Cr(VI) through the more reactive Cr(V) and Cr(IV) valences to Cr(III) (O'Brien et al. 2003); however, evidence of the role of reactive oxygen species in the genotoxicity of Cr(VI) is inconsistent (Chorvatovicova et al. 1991; O'Brien et al. 2003; Standeven and Wetterhahn 1991; Zhitkovich 2005). Cr(III), the final product of intracellular reduction of Cr(VI), has been shown to interact directly with DNA and other macromolecules to induce chromosomal alterations and mutational changes (O'Brien et al. 2003; Quievryn et al. 2006; Reynolds et al. 2007; Zhitkovich 2005). DNA adducts, DNA-protein crosslinks, and DNA-interstrand crosslinks have all been identified as products of Cr(III)-DNA interactions. The relative contributions of the multiple, complex pathways of chromium-induced genotoxicity continue to be investigated.

In conclusion, the NTP 2-year study of SDD is the first and only lifetime study that clearly demonstrates the carcinogenicity of Cr(VI) in rats and mice following oral exposure. In addition, toxicity to the erythron, increased incidences of non-neoplastic lesions in multiple tissues and increased tissue chromium concentrations demonstrate systemic exposure and toxicity.

References

ATSDR. 2000. Toxicological Profile for Chromium. Atlanta, GA: Agency for Toxic Substances and Disease Registry.

Bailer AJ, Portier CJ. 1988. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. *Biometrics* 44:417-431.

Beaumont JJ, Sedman RM, Reynolds SD, Sherman CD, Li LH, Howd RA, et al. 2008. Cancer mortality in a Chinese population exposed to hexavalent chromium in drinking water. *Epidemiology* 19:12-23.

Boorman GA, Montgomery CA, Jr, Eustis SL, Wolfe MJ, McConnell EE, Hardisty JF. 1985. Quality assurance in pathology for rodent carcinogenicity studies. In: *Handbook of Carcinogen Testing* (Milman HA, Weisburger EK, eds). Park Ridge, NJ: Noyes Publications, 345-357.

Borneff J, Engelhardt K, Griem W, Kunte H, Reichert J. 1968. Carcinogens in water and soil. XXII. Experiment with 3,4-benzopyrene and potassium chromate in mice drink [in German]. *Arch Hyg Bakteriol* 152:45-53.

CDPH (California Department of Public Health). 2007a. Chromium-6 in Drinking Water Standard: Sampling Results. Available: <http://ww2.cdph.ca.gov/certlic/drinkingwater/Pages/Chromium6sampling.aspx> [accessed 10 November 2008]

CDPH (California Department of Public Health). 2007b. Chromium-6 in Drinking Water: Regulation Update. Available: <http://ww2.cdph.ca.gov/certlic/drinkingwater/Pages/Chromium6.aspx> [accessed 10 November 2008]

Chorvatovicova D, Ginter E, Kosinova A, Zloch Z. 1991. Effect of vitamins C and E on toxicity and mutagenicity of hexavalent chromium in rat and guinea pig. *Mutat Res* 262:41-46.

CFR (Code of Federal Regulations) 21, Part 58.

Cohen MD, Kargacin B, Klein CB, Costa M. 1993. Mechanisms of chromium carcinogenicity and toxicity. *Crit Rev Toxicol* 23:255-281.

Costa M. 1997. Toxicity and carcinogenicity of Cr(VI) in animal models and humans. *Crit Rev Toxicol* 27:431-442.

Costa M, Klein CB. 2006. Toxicity and carcinogenicity of chromium compounds in humans. *Crit Rev Toxicol* 36:155-163.

Cox DR. 1972. Regression models and life-tables. *J R Stat Soc B34*, 187-220.

De Flora S. 2000. Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. *Carcinogenesis* 21:533-541.

De Flora S, Camoirano A, Bagnasco M, Bennicilli C, Corbett GE, Kerger BD. 1997. Estimates of the chromium (VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. *Carcinogenesis* 18:531-537.

De Flora S, Bagnasco M, Serra D, Znacchi P. 1990. Genotoxicity of chromium compounds. A review. *Mutat Res* 238:99-172.

DeFlora S, D'Agostini F, Balansky R, Micale R, Baluce B, Izzotti A. 2008. Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water. *Mutat Res* 659:60-67

Dixon WJ, Massey FJ, Jr. 1957. *Introduction to Statistical Analysis*. 2nd ed. New York: McGraw-Hill.

Donaldson RM, Jr, Barreras, RF. 1966. Intestinal absorption of trace quantities of chromium. *J Lab Clin Med* 68:484-493.

Dunn OJ. 1964. Multiple comparisons using rank sums. *Technometrics* 6:241-252.

Dunnett CW. 1955. A multiple comparison procedure for comparing several treatments with a control. *J Am Stat Assoc* 50:1096-1121.

Febel H, Szegedi B, Huszar S. 2001. Absorption of inorganic, trivalent and hexavalent chromium following oral and intrajejunal doses in rats. *Acta Vet Hung* 49:203-209.

IARC. 1990. Chromium. *IARC Monogr Eval Carcinog Risks Hum* 49:49-256.

Jonckheere AR. 1954. A distribution-free k -sample test against ordered alternatives. *Biometrika* 41:133-145.

Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457-481.

Maronpot RR, Boorman GA. 1982. Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol Pathol* 10:71-80.

McConnell EE, Solleveld HA, Swenberg JA, Boorman GA. 1986. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *J Natl Cancer Inst* 76:283-289.

NCI. 1977. Bioassay of Captan for Possible Carcinogenicity (CAS No. 133-06-2). Technical Report 15. Bethesda, MD: National Cancer Institute.

NTP. 1993. Toxicology and Carcinogenesis Studies of 1,2,3-Trichloropropane (CAS No. 96-18-4) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Technical Report 384. Research Triangle Park, NC: National Toxicology Program.

NTP. 1998. Report on Carcinogens. 8th ed. Research Triangle Park, NC: National Toxicology Program.

NTP. 2007. Toxicity Studies of Sodium Dichromate Dihydrate (CAS No. 7789-12-0) Administered in Drinking Water to Male and Female F344/N Rats and B6C3F1 Mice and Male BALB/c and *am3*-C57BL/6 Mice. Toxicity Report 72. Research Triangle Park, NC: National Toxicology Program.

NTP. 2008a. Toxicology and Carcinogenesis Studies of Sodium Dichromate Dihydrate (CAS No. 7789-12-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies). Technical Report 546. Research Triangle Park, NC: National Toxicology Program.

NTP. 2008b. Toxicology and Carcinogenesis Studies of Chromium Picolinate Monohydrate (CAS No. 27882-76-4) in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical Report 556. Research Triangle Park, NC: National Toxicology Program (draft).

Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. 1996. Applied Linear Statistical Models, 4th ed. Boston: WCB McGraw-Hill, Boston. pp 115-124.

O'Brien TJ, Ceryak S, Patierno SR. 2003. Complexities of chromium carcinogenesis: Role of cellular response, repair, and recovery mechanisms. *Mutat Res* 533:3-36.

Pellerin C, Booker SM. 2000. Reflections on hexavalent chromium: Health hazards of an industrial heavyweight. *Environ. Health Perspect.* 108:A402-A407.

Piegorsch WW, Bailer AJ. 1997. *Statistics for Environmental Biology and Toxicology*. London: Chapman and Hall.

Portier CJ, Bailer AJ. 1989. Testing for increased carcinogenicity using a survival-adjusted quantal response test. *Fundam Appl Toxicol* 12:731-737.

Proctor DM, Otani JM, Finley BL, Paustenbach DJ, Bland JA, Speizer N, et al. 2002. Is hexavalent chromium carcinogenic via ingestion? A weight-of-evidence review. *J Toxicol Environ Health A* 65:701-746.

Quievryn G, Messer J, Zhitkovich A. 2006. Lower mutagenicity but higher stability of Cr-DNA adducts formed during gradual chromate activation with ascorbate. *Carcinogenesis* 27:2316-2321.

Reynolds M, Stoddard L, Bessalov I, Zhitkovich, A. 2007. Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: Linkage to DNA breaks in G2 phase by mismatch repair. *Nucleic Acids Res.* 35:465-476.

Sedman RM, Beaumont J, McDonald TA, Reynolds S, Krowech G, Howd R. 2006. Review of the evidence regarding the carcinogenicity of hexavalent chromium in drinking water. *J Environ Sci Health C* 24:155-182.

Shackelford CC, Elwell MR. 1999. Small and large intestine, and mesentery. In: *Pathology of the Mouse* (Maronpot RR, ed). Vienna, IL: Cache River Press, 81-118.

Shirley E. 1977. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* 33:386-389.

Standeven AM, Wetterhahn KE. 1991. Is there a role for reactive oxygen species in the mechanism of chromium(VI) carcinogenesis? *Chem Res Toxicol* 4:616-625.

Tarone RE. 1975. Tests for trend in life table analysis. *Biometrika* 62:679-682.

U.S. EPA. 1998. Toxicological Review of Hexavalent Chromium (CAS No. 18540-29-9). In *Support of Summary Information on the Integrated Risk Information System (IRIS)*. Washington DC: U.S. Environmental Protection Agency.

Williams DA. 1986. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. *Biometrics* 42:183-186.

Zhang JD, Li XL. 1987. Chromium pollution of soil and water in Jinzhou [in Chinese].

Zhonghua Yu Fang Yi Xue Za Zhi 21: 262-264.

Zhitkovich A. 2005. Importance of chromium—DNA adducts in mutagenicity and toxicity of chromium (VI). Chem Res Toxicol 18:3-9.

Table 1. Concentrations in drinking water (mg/L) and average daily ingested doses (mg/kg) of SDD and Cr(VI) following exposure for 2 years.

	SDD (mg/L)	Cr(VI) ^a (mg/L)	SDD ^b (mg/kg)	Cr(VI) ^c (mg/kg)
Male Rats	0	0	0	0
	14.3	5	0.6	0.2
	57.3	20	2.2	0.8
	172	60	6	2.1
	516	180	17	5.9
Female Rats	0	0	0	0
	14.3	5	0.7	0.2
	57.3	20	2.7	0.9
	172	60	7	2.4
	516	180	20	7.0
Male Mice	0	0	0	0
	14.3	5	1.1	0.4
	28.6	10	2.6	0.9
	85.7	30	7	2.4
	257.4	90	17	5.9
Female Mice	0	0	0	0
	14.3	5	1.1	0.4
	57.3	20	3.9	1.4
	172	60	9	3.1
	516	180	25	8.7

SDD=sodium dichromate dihydrate;

Cr(VI)=hexavalent chromium;

^aCalculated using the drinking water concentration of SDD and the percent mass of Cr(VI) in SDD;

^bCalculated using body weight and water consumption data;

^cCalculated using the average daily dose of SDD and the percent mass of Cr(VI) in SDD.

Table 2. Squamous cell neoplasms of the oral cavity (oral mucosa and tongue) of F344/N rats exposed to SDD for 2 years in drinking water.

Concentration	Historical Control Incidence ^a (Range)		Incidence/number of animals examined (Survival adjusted % incidence) ^b				
	Drinking Water	All Routes	0 mg/L	14.3 mg/L	57.3 mg/L	172 mg/L	516 mg/L
Males							
Oral Mucosa							
Carcinoma	0/350	5/1,499 (0-2%)	0/50***	0/50	0/49	0/50	6/49 (13.6) ^{c*}
Tongue							
Papilloma	ND ^c	ND	0/50	0/50	0/49	0/50	1/49 (2.3)
Carcinoma	ND	ND	0/50	1/50 (2.4)	0/49	0/50	0/49
Oral Mucosa or Tongue							
Papilloma or carcinoma combined	1/350 (0-2%)	10/1,499 (0-2%)	0/50***	1/50 (2.4)	0/49	0/50	7/49 (15.7)**
Females							
Oral Mucosa							
Carcinoma	0/300	5/1,400 (0-2%)	0/50***	0/50	0/50	2/50 [#] (4.6)	11/50 (23.9)***
Tongue							
Papilloma	ND	ND	1/50 (2.2)	1/50 (2.3)	0/50	0/50	0/50
Carcinoma	ND	ND	0/50	0/50	0/50	1/50 (2.3)	0/50
Oral Mucosa or Tongue							
Papilloma or carcinoma combined	4/300 (0-2%)	15/1,400 (0-6%)	1/50 (2.2)***	1/50 (2.3)	0/50	2/50 [§] (4.6)	11/50 (23.9)**

SDD=Sodium dichromate dihydrate;

ND=Not determined;

^aThe NTP historical database contains all studies that use the NTP-2000 diet with histopathology findings completed within the most recent 5-year period, including the present study;

^bCalculated using the poly-3 test;

^cHistorical control incidences are not determined for the tongue because it is not an NTP protocol-required tissue;

*Significantly different than the control group by the poly-3 test or a significant trend if assigned to a control group (*P≤0.05); **P≤0.01; ***P≤0.001;

[#]The incidence exceeded the historical control range for both drinking water studies and all routes but was not significantly increased compared to the concurrent control;

[§]The incidence exceeded the historical control range for drinking water studies but was not significantly increased compared to the concurrent control

Table 3. Epithelial neoplasms of the small intestine in B6C3F1 mice exposed to SDD in drinking water for 2-years.

	Historical Control Incidence ^a (Range)		Incidence/number of animals examined (Survival adjusted % incidence) ^b				
	Drinking Water	All Routes	0 mg/L	14.3 mg/L	28.6 mg/L	85.7 mg/L	257.4 mg/L
Males							
Concentration			0 mg/L	14.3 mg/L	28.6 mg/L	85.7 mg/L	257.4 mg/L
Duodenum							
Adenoma (includes multiple)	6/299 (0-6%)	9/1,549 (0-6%)	1/50 ^b (2.2) ^{c***}	0/50	1/50 (2.3)	5/50 [#] (10.8)	15/50 (32.9) ^{***}
Carcinoma	1/299 (0-2%)	3/1,549 (0-4%)	0/50*	0/50	0/50	2/50 [§] (4.3)	3/50 [#] (6.8)
Jejunum							
Adenoma	0/299	1/1,549 (0-2%)	0/50**	0/50	0/50	0/50	3/50 [#] (6.8)
Carcinoma (includes multiple)	5/299 (0-4%)	25/1,549 (0-8%)	0/50	2/50 (4.5)	0/50	1/50 (2.2)	2/50 (4.6)
Duodenum, Jejunum or Ileum (combined)							
Adenoma	6/299 (0-6%)	10/1,549 (0-6%)	1/50 (2.2) ^{***}	1/50 (2.3)	1/50 (2.3)	5/50 [#] (10.8)	17/50 (37.2) ^{***}
Carcinoma	6/299 (0-4%)	30/1,549 (0-8%)	0/50*	2/50 (4.5)	1/50 (2.3)	3/50 [§] (6.5)	5/50 (11.4) [*]
Adenoma or Carcinoma (combined)	11/299 (0-10%)	39/1,549 (0-10%)	1/50 (2.2) ^{***}	3/50 (6.8)	2/50 (4.6)	7/50 (15.1) [*]	20/50 (43.8) ^{***}
Females							
Concentration			0 mg/L	14.3 mg/L	57.3 mg/L	172 mg/L	516 mg/L
Duodenum							
Adenoma (includes multiple)	1/350 (0-2%)	3/1,648 (0-2%)	0/50 ^{***}	0/50	2/50 [#] (4.2)	13/50 (27.8) ^{***}	12/50 (25.2) ^{***}
Carcinoma	0/350	1/1,648 (0-2%)	0/50 ^{***}	0/50	0/50	1/50 [§] (2.1)	6/50 (12.6) ^{b*}
Jejunum							
Adenoma (includes multiple)	0/350	0/1,648	0/50 ^{**}	1/50 [#] (2.2)	0/50	2/50 [#] (4.3)	5/50 (10.6) [*]
Carcinoma	2/350 (0-2%)	5/1,648 (0-2%)	1/50 (2.2)	0/50	2/50 [#] (4.2)	2/50 [#] (4.3)	1/50 (2.1)
Duodenum, Jejunum or Ileum (combined)							
Adenoma	1/350 (0-2%)	3/1,648 (0-2%)	0/50 ^{***}	1/50 (2.2)	2/50 [#] (4.2)	15/50 (32.0) ^{***}	16/50 (33.7) ^{***}
Carcinoma	3/350 (0-2%)	8/1,648 (0-2%)	1/50 (2.2) ^{***}	0/50	2/50 [#] (4.2)	3/50 [#] (6.4)	7/50 (14.7) [*]
Adenoma or Carcinoma (combined)	4/350 (0-4%)	11/1,648 (0-4%)	1/50 (2.2) ^{***}	1/50 (2.2)	4/50 [#] (8.3)	17/50 (36.3) ^{***}	22/50 (45.9) ^{***}

SDD=Sodium dichromate dihydrate

^aThe NTP historical database contains all studies that use the NTP-2000 diet with histopathology findings completed within the most recent 5-year period, including the present study;

^bCalculated using the poly-3 test;

^{*}Significantly different than the control group by the poly-3 test or a significant trend if assigned to a control group (*P≤0.05);**P≤0.01; ***P≤0.001;

[#]The incidence exceeded the historical control range for both drinking water studies and all routes but was not significantly increased compared to the concurrent control;

[§]The incidence exceeded the historical control range for drinking water studies but was not significantly increased compared to the concurrent control

Table 4. Focal and diffuse hyperplasia of the small intestine in B6C3F1 mice exposed to sodium dichromate dihydrate in drinking water for 2-years.

Males					
Concentration	0 mg/L	14.3 mg/L	28.6 mg/L	85.7 mg/L	257.4 mg/L
Duodenum					
Epithelium, Hyperplasia,					
Focal	0/50 ^a	0/50	0/50	1/50 (3.0) ^b	2/50 (3.5)
Diffuse	0/50	11/50** (2.0)	18/50** (1.6)	42/50** (2.1)	32/50** (2.1)
Females					
Concentration	0 mg/L	14.3 mg/L	57.3 mg/L	172 mg/L	516 mg/L
Duodenum					
Epithelium, Hyperplasia					
Focal	0/50	0/50	1/50 (2.0)	2/50 (3.0)	0/50
Diffuse	0/50	16/50** (1.6)	35/50** (1.7)	31/50** (1.6)	42/50** (2.2)
Jejunum					
Epithelium, Hyperplasia					
Diffuse	0/50	2/50 (2.0)	1/50 (2.0)	0/50	8/50** (1.9)

^aIncidence


^bMean severity: 1=minimal; 2=mild; 3=moderate; 4=marked;

*Significant by poly-3 test ($P \leq 0.05$); ** ($P \leq 0.01$)

Figure Legend

Figure 1. (A) Low magnification of a section of the nasal cavity demonstrating the location of a squamous cell carcinoma (arrows) arising from the oral mucosa of the soft palate. The neoplasm has invaded the adjacent submucosal tissue and surrounded a molar tooth. Male rat given 516 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar: 500 μm . (B) Higher magnification of A, demonstrating the malignant features of the squamous cell carcinoma. Islands and cords of dysplastic squamous epithelium (arrows) are surrounded by dense proliferative connective tissue stroma. Male rat given 516 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar: 100 μm . (C) Squamous cell carcinoma projecting from the dorsal mucosal surface of the tongue (arrows). Female rat given 14.3 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar: 500 μm . (D) Adenoma of the duodenum (arrows) has distorted and replaced a segment of the mucosa and protruded into the lumen. Normal mucosal is seen opposite to the adenoma. Female mouse given 516 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar, 200 μm . (E) Carcinoma of the duodenum (arrows) has effaced the mucosa invading the submucosa, muscle layers and the pancreas. Male mouse given 257.4 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar, 200 μm . (F) Focal hyperplasia of the duodenum (arrows) occurring in the superficial mucosa. Male mouse given 172 mg/L sodium dichromate dihydrate for 2 years. H&E. Scale Bar, 100 μm . (G) Duodenum from a control female mouse demonstrating normal microscopic anatomy. Note tall, slender villi (arrows) lined by a single layer of tall columnar epithelial cells. Control female. H&E. Scale Bar, 50 μm . (H) Diffuse hyperplasia in the duodenum. Duodenal villi are short, wide and blunt and lined by hyperplastic epithelial cells that are piling up along the villi (arrows). Note histiocyte infiltrates expanding the lamina propria at the tips of the villi (asterisks). Female mouse given 516 mg/L

sodium dichromate dihydrate for 2 years. H&E. Scale Bar, 50 μ m.



190x279mm (300 x 300 DPI)